Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance.
Melissa L BorgJulie MassartThais De Castro BarbosaAdrià Archilla-OrtegaJonathon A B SmithJohanna T LannerJorge Alsina-FernandezBenjamin YadenAlexander E CulverHåkan K R KarlssonJoseph T BrozinickJuleen R ZierathPublished in: Journal of cachexia, sarcopenia and muscle (2021)
Modified human UCN2 is a pharmacological candidate for the prevention of the loss of skeletal muscle mass associated with obesity and immobilization.
Keyphrases
- insulin resistance
- high fat diet induced
- metabolic syndrome
- adipose tissue
- type diabetes
- high fat diet
- endothelial cells
- skeletal muscle
- weight loss
- high glucose
- polycystic ovary syndrome
- mouse model
- weight gain
- diabetic rats
- oxidative stress
- drug induced
- pluripotent stem cells
- body mass index
- combination therapy
- replacement therapy